Definium Therapeutics, Inc. · NASDAQ:DFTX
Definium Therapeutics — Mind Medicine (MindMed) — Proxy Contest (May 2023)
14 slides from Definium Therapeutics's proxy contest presentation, May 31, 2023
Slide 1: MindMed: FCM's Claims vs. Reality
Mindmed FCM’s Claims vs. Reality May 2023.
Slide 2: Cautionary Notes and Forward-Looking Statements
Disclaimer Mindmed Cautionary Notes and Forward-Looking Statements Certain statements in this presentation related to Mind Medicine (MindMed) Inc. (the “Company” or “MindMed”) constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. For
Slide 3: Protecting MindMed Shareholders
Protecting MindMed Shareholders Mindmed MindMed is highly concerned by FCM’s continued willingness to mislead shareholders In its materials, FCM relies on cherry picked data, distortions and falsehoods to support why it should be given control of MindMed’s Board We believe that FCM has been willing
Slide 4: FCM Blatantly Misrepresents the Qualifications of Our Nominees
FCM Blatantly Misrepresents the Qualifications of Our Nominees Mindmed FCM’S CLAIM REALITY Over a decade of experience leading drug development programs Industry-leading experience in clinical and regulatory strategy for psychedelics, particularly in psychiatry Extensive board and financial leadersh
Slide 5: FCM's Cherry Picked Engagement Timeline
FCM’s Cherry Picked Engagement Timeline Mindmed FCM’S CLAIM REALITY FCM’s distortions and omissions from its engagement with MindMed are too numerous to list, but include: At Scott Freeman’s request, the Board invited him to be part of the Nominating and Corp Gov. Committee’s process for selecting n
Slide 6: FCM is Trying to Rewrite the History of MM-110
LOGO FCM is Trying to Rewrite the History of MM 110 FCM’S CLAIM REALITY DISTORTING Scott Freeman attempted to develop MM 110 (then called 18 MC) for approximately nine years before he and his co founder folded the program into MindMed A fter receiving adverse FDA feedback in 2014, Scott Freeman did
Slide 7: FCM Makes No Effort to Support its False Allegations
LOGO FCM Makes No Effort to Support its False Allegations Because it Can’t FCM’S CLAIM REALITY “…the formulation in the LSD assist ( lysergide in solution) is different from MM 120 lysergide D tartrate in solid oral dosage form)…” – Dr. Matthias Liechti , UHB Principal Investigator “The target popul
Slide 8: FCM's Attempt to Spin the Greenleaf Findings Falls Flat
LOGO FCM’s Attempt to Spin the Greenleaf Findings Falls Flat FCM’S CLAIM REALITY Greenleaf health Study, Quoting FDA, Supports FCM’s Plan to Immediately start an LSD Phase III Trial FCM Concerned MindMed’s Mismanagement Threatens Mental Health for Millions And the very next day, an industry sell sid
Slide 9: FCM Makes its Financial Inexperience Clear
LOGO FCM Makes its Financial Inexperience Clear FCM’S CLAIM REALITY INACCURATE Cash Runway for Pre-Revenue Psychedelics Peers2 Cash runway < 2024 Cash runway into 2025 or thereafter If MindMed hadn’t raised capital when it did, we would be facing an uncertain future without the resources to progress
Slide 10: FCM's Budget Would Put Achieving Key Milestones at Risk
LOGO FCM’s Budget Would Put Achieving Key Milestones at Risk FCM’S CLAIM REALITY ? Relative to our closest sector peers, we spend materially less on SG&A in absolute and percentage terms and dedicate more of our resources towards R&D FCM’s budget seems based on nothing more than “spreadsheet math” a
Slide 11: FCM Claims About Compensation Are Simply False
FCM Claims About Compensation Are Simply False FCM’S CLAIM REALITY MindMed’s executive compensation is directly linked to performance Over 80% of NEOs’ 2022 total direct compensation is structured to be “at-risk” with payout and value dependent company performance Realizable pay reflects the impact
Slide 12: Who Do You Trust?
Who Do You Trust? FCM Mindmed Unqualified nominees that do not possess the skills or experience to lead MindMed through this pivotal period A plan that has no credible basis, ignores multiple third party expert analyses and would expose the Company to significant risk A former co-founder who is atte
Slide 13: Vote the WHITE Universal Proxy Card to Protect MindMed
Vote the WHITE Universal Proxy Card to Protect MindMed Mindmed PROTECT YOUR INVESTMENT IN MINDMED Vote MindMed’s WHITE universal proxy card to vote “FOR” MindMed’s six highly qualified nominees, FOR the other proposals recommended by MindMed and WITHHOLD on FCM’s nominees www.ProtectMindMed.com INVE
Slide 14: 3) MindMed)
3) MindMed)